Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Muscle represents an important tissue target for adeno‐associated virus (AAV) vector‐mediated gene transfer in muscular, metabolic or blood‐related genetic disorders. However, several studies have demonstrated the appearance of immune responses against the transgene product after intramuscular AAV vector delivery that resulted in a limited efficacy of the treatment. Use of microRNAs that are specifically expressed in antigen‐presenting cells (APCs) is a promising approach for avoiding those immune responses. Cellular mir‐142‐3p, which is APC‐specific, is able to repress the translation of its target cellular transcripts by binding to a specific target sequences. Methods: In the present study, we explored the potential of mir‐142‐3p specific target sequences with respect to reducing or abolishing immune responses directed against ovalbumin (OVA), a highly immunogenic protein, expressed as transgene and delivered by AAV1 vector administered intramuscularly. Results: The occurrence of immune responses against OVA transgene following intramuscular delivery by AAV have been described previously and resulted in the loss of OVA protein expression. In the present study, we demonstrate that OVA protein expression was maintained when mir‐142‐3pT sequences were incorporated into the expression cassette. The sustained expression of OVA protein over time correlated with a reduced increase in anti‐OVA antibody levels. Furthermore, no cellular infiltrates were observed in the muscle tissue when AAV1 vectors containing four or eight repeats of mir‐142‐3p target sequences after the OVA sequence were used. Conclusions: The rising humoral and cellular immune responses against OVA protein after intramuscular delivery can be efficiently reduced by the use of mir‐142‐3p target sequences. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“They have been successfully employed in the treatment of genetic disorders in preclinical studies [8–11], as well as in clinical trials [1,3,12,13].”
MethodGene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Gene therapy using adeno-associated virus vectors
Daya, S., & Berns, K. I. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-08 · Cited by 926 · cited 1×
“Furthermore, AAV vectors are not associated with any pathology and are replication-defective [7].”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 3×
“However, immune suppression protocols have not always proven to be effective [29], as observed in a clinical study where AAV-based gene therapy was used in patients with Duchenne’s muscular dystrophy [27].”
BackgroundMethodResultRecombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345 · cited 1×
“They have been successfully employed in the treatment of genetic disorders in preclinical studies [8–11], as well as in clinical trials [1,3,12,13].”
Method
Research works printed but not linked: 40
- 10.1182/blood-2009-12-261156 · DOI · Paper page
- 10.1182/blood-2011-09-377630 · DOI · Paper page
- 10.1182/blood-2008-10-181479 · DOI · Paper page
- 10.1126/science.1104297 · DOI · Paper page
- 10.1089/hum.2004.15.906 · DOI · Paper page
- 10.1089/hum.2006.17.487 · DOI · Paper page
- 10.1016/j.atherosclerosissup.2010.03.004 · DOI
- 10.1016/j.neulet.2012.04.078 · DOI · Paper page
- 10.1089/hum.2007.042 · DOI · Paper page
- 10.1073/pnas.93.24.14082 · DOI · Paper page
- 10.1046/j.1365-2141.1996.6192064.x · DOI
- 10.1038/mt.2010.73 · DOI · Paper page
- 10.1111/j.1365-2516.2008.01917.x · DOI
- 10.1182/blood.V97.12.3733 · DOI · Paper page
- 10.1038/sj.gt.3302539 · DOI
- 10.1073/pnas.0909520106 · DOI · Paper page
- 10.1182/blood-2004-03-0848 · DOI · Paper page
- 10.1038/sj.gt.3301829 · DOI
- 10.1038/mt.2009.150 · DOI · Paper page
- 10.1056/NEJMra064928 · DOI · Paper page
- 10.1016/S0092-8674(01)00616-X · DOI · Paper page
- 10.1038/nrg1328 · DOI · Paper page
- 10.1126/science.1091903 · DOI · Paper page
- 10.1016/S0960-9822(02)00809-6 · DOI · Paper page
- 10.1182/blood-2009-04-214569 · DOI · Paper page
- 10.1038/mt.2010.290 · DOI · Paper page
- 10.1089/10430340260355347 · DOI · Paper page
- 10.1128/JVI.70.11.8098-8108.1996 · DOI · Paper page
- 10.1128/JVI.70.11.8098-8108.1996 · DOI · Paper page
- 10.1182/blood-2004-03-0848 · DOI · Paper page
- 10.1006/clim.1999.4724 · DOI · Paper page
- Manning WC, 1997, Genetic immunization with adeno‐associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D, J Virol, 71, 7960, 10.1128/jvi.71.10.7960-7962.1997 · DOI · Paper page
- 10.1128/JVI.75.1.269-277.2001 · DOI · Paper page
- 10.1089/1043034041648453 · DOI · Paper page
- 10.1006/mthe.2001.0496 · DOI · Paper page
- 10.1038/nrg1379 · DOI · Paper page
- 10.1016/S0960-9822(02)00809-6 · DOI · Paper page
- 10.1038/nbt1372 · DOI · Paper page
- 10.1371/journal.pone.0033286 · DOI
- Boisgerault F, 2010, Impact of the Host Environment on the Control of Gene Transfer-Induced Immune Responses with miRNA 142.3p‐Regulated Vectors, Mol Ther, 18, S1
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Metadata
- Authors
- Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2013-06
- Volume
- 15
- Issue
- 6-7
- Pages
- 219-232
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W1519797983
- Cited by
- 71
- References
- 18
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery. https://app.cochat.ai/papers/10.1002/jgm.2712
- The paper
- Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V. (2013). Mir‐142‐3p target sequences reduce transgene‐directed immunogenicity following intramuscular adeno‐associated virus 1 vector‐mediated gene delivery. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.2712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.